| First Author | Nocera DA | Year | 2016 |
| Journal | J Immunol | Volume | 196 |
| Issue | 6 | Pages | 2860-9 |
| PubMed ID | 26880763 | Mgi Jnum | J:353171 |
| Mgi Id | MGI:7664224 | Doi | 10.4049/jimmunol.1501044 |
| Citation | Nocera DA, et al. (2016) In Vivo Visualizing the IFN-beta Response Required for Tumor Growth Control in a Therapeutic Model of Polyadenylic-Polyuridylic Acid Administration. J Immunol 196(6):2860-9 |
| abstractText | The crucial role that endogenously produced IFN-beta plays in eliciting an immune response against cancer has recently started to be elucidated. Endogenous IFN-beta has an important role in immune surveillance and control of tumor development. Accordingly, the role of TLR agonists as cancer therapeutic agents is being revisited via the strategy of intra/peritumoral injection with the idea of stimulating the production of endogenous type I IFN inside the tumor. Polyadenylic-polyuridylic acid (poly A:U) is a dsRNA mimetic explored empirically in cancer immunotherapy a long time ago with little knowledge regarding its mechanisms of action. In this work, we have in vivo visualized the IFN-beta required for the antitumor immune response elicited in a therapeutic model of poly A:U administration. In this study, we have identified the role of host type I IFNs, cell populations that are sources of IFN-beta in the tumor microenvironment, and other host requirements for tumor control in this model. One single peritumoral dose of poly A:U was sufficient to induce IFN-beta, readily visualized in vivo. IFN-beta production relied mainly on the activation of the transcription factor IFN regulatory factor 3 and the molecule UNC93B1, indicating that TLR3 is required for recognizing poly A:U. CD11c(+) cells were an important, but not the only source of IFN-beta. Host type I IFN signaling was absolutely required for the reduced tumor growth, prolonged mice survival, and the strong antitumor-specific immune response elicited upon poly A:U administration. These findings add new perspectives to the use of IFN-beta-inducing compounds in tumor therapy. |
